Arno Therapeutics will use JNJ's Veridex LLC unit's Cellsearch technology to isolate CTCs and analyze the cells for activated progesterone receptors to help enroll patients who may benefit from treatment with onapristone

Arno Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Johnson & Johnson

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced